↓ Skip to main content

Shortened tuberculosis treatment regimens: what is new?

Overview of attention for article published in Mar-Apr 2020, January 2020
Altmetric Badge

Mentioned by

6 news outlets


5 Dimensions

Readers on

23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Shortened tuberculosis treatment regimens: what is new?
Published in
Mar-Apr 2020, January 2020
DOI 10.36416/1806-3756/e20200009
Pubmed ID

Denise Rossato Silva, Fernanda Carvalho de Queiroz Mello, Giovanni Battista Migliori


Given the global burden of tuberculosis, shortened treatment regimens with existing or repurposed drugs are needed to contribute to tuberculosis control. The long duration of treatment of drug-susceptible tuberculosis (DS-TB) is associated with nonadherence and loss to follow up, and the treatment success rate of multidrug-resistant tuberculosis (MDR-TB) is low (approximately 50%) with longer regimens. In this review article, we report recent advances and ongoing clinical trials aimed at shortening regimens for DS-TB and MDR-TB. We discuss the role of high-dose rifampin, as well as that of clofazimine and linezolid in regimens for DS-TB. There are at least 5 ongoing clinical trials and 17 observational studies and clinical trials evaluating shorter regimens for DS-TB and MDR-TB, respectively. We also report the results of observational studies and clinical trials evaluating a standardized nine-month moxifloxacin-based regimen for MDR-TB. Further studies, especially randomized clinical trials, are needed to evaluate regimens including newer drugs, drugs proven to be or highly likely to be efficacious, and all-oral drugs in an effort to eliminate the need for injectable drugs.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 26%
Professor > Associate Professor 2 9%
Other 2 9%
Researcher 2 9%
Student > Ph. D. Student 2 9%
Other 4 17%
Unknown 5 22%
Readers by discipline Count As %
Medicine and Dentistry 5 22%
Chemistry 2 9%
Immunology and Microbiology 2 9%
Veterinary Science and Veterinary Medicine 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Other 2 9%
Unknown 10 43%